AtriCure CSO sells 5,000 company shares

AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares of common stock in an open-market transaction at a price of $28.13 per share.

Rhea-AI Filing Summary

AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares of common stock in an open-market transaction at a price of $28.13 per share. After this sale on May 15, he directly holds 91,875 AtriCure common shares.

Insights

Insider transactions analyst

CSO executes a modest open-market share sale.

Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares of AtriCure common stock at $28.13 per share in an open-market transaction. This is a straightforward sale of non-derivative shares, not tied to an option exercise or conversion.

Following the sale, he holds 91,875 shares directly, indicating he retains a substantial equity position relative to the shares sold. With no derivatives reported in this filing, the visible equity exposure is entirely in common stock. The filing does not reference any pre-arranged trading plan.

Insider Trade Summary

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Doraiswamy Vinayak

Role Chief Scientific Officer

Sold 5,000 shs ($141K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,000	$28.13	$141K

Holdings After Transaction: Common Stock — 91,875 shares (Direct)

Key Figures

Shares sold: 5,000 shares Sale price: $28.13 per share Shares owned after sale: 91,875 shares +1 more

4 metrics

Shares sold 5,000 shares Open-market sale of common stock

Sale price $28.13 per share Price for the 5,000-share open-market sale

Shares owned after sale 91,875 shares Direct holdings following the transaction

Net share change -5,000 shares Net buy/sell direction in transaction summary

Key Terms

Form 4, open-market sale, non-derivative, transaction code "S"

4 terms

Form 4 regulatory

"AtriCure reported the transaction on a Form 4 insider trading filing."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market sale financial

"The open-market sale was executed at $28.13 per share."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"This is a straightforward sale of non-derivative shares, not tied to an option exercise."

transaction code "S" regulatory

"The Form 4 describes a code “S” transaction, indicating a sale in the open market."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AtriCure (ATRC) report for Doraiswamy Vinayak?

AtriCure reported that Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares of common stock. The open-market sale was executed at $28.13 per share, and it was reported on a Form 4 insider trading filing.

At what price did AtriCure (ATRC) insider Doraiswamy Vinayak sell shares?

Doraiswamy Vinayak sold his AtriCure common shares at $28.13 per share. This price applies to the 5,000-share open-market transaction disclosed, giving investors clarity on the level at which the sale occurred.

How many AtriCure (ATRC) shares does Doraiswamy Vinayak hold after the sale?

After the reported sale, Doraiswamy Vinayak holds 91,875 AtriCure common shares directly. This post-transaction balance shows he maintains a significant remaining ownership stake despite the 5,000-share sale.

Was the AtriCure (ATRC) insider transaction an open-market sale?

Yes, the transaction was classified as an open-market sale of common stock. The Form 4 describes a code “S” transaction, indicating a sale in the open market or private transaction at $28.13 per share.

Did AtriCure (ATRC) report any derivative exercises for Doraiswamy Vinayak?

No derivative transactions were reported for Doraiswamy Vinayak in this Form 4. The filing lists only a non-derivative common stock sale, and the derivative holdings summary is empty in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doraiswamy Vinayak

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OHIO 45040-9695

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		S		5,000	D	$28.13	91,875	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Vinayak S. Doraiswamy	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)